uniQure (NASDAQ:QURE) Price Target Lowered to $60.00 at Wells Fargo & Company

uniQure (NASDAQ:QURE) had its price target lowered by equities researchers at Wells Fargo & Company from $80.00 to $60.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 101.55% from the stock’s previous close.

QURE has been the topic of a number of other research reports. Stifel Nicolaus raised their price objective on uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. HC Wainwright lowered their price target on shares of uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Cantor Fitzgerald upped their price objective on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. Guggenheim raised their target price on shares of uniQure from $28.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Finally, Mizuho increased their price target on uniQure from $30.00 to $60.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $64.42.

uniQure Price Performance

Shares of QURE traded down $1.07 during mid-day trading on Wednesday, hitting $29.77. 1,006,966 shares of the company were exchanged, compared to its average volume of 2,225,363. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -7.59 and a beta of 0.59. uniQure has a 1-year low of $5.50 and a 1-year high of $71.50. The company has a 50 day moving average of $42.55 and a 200-day moving average of $24.50. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. Analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Insider Activity at uniQure

In related news, Director Jack Kaye sold 38,810 shares of the business’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the sale, the director owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Gut sold 31,434 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $27.26, for a total value of $856,890.84. Following the transaction, the director directly owned 40,145 shares in the company, valued at approximately $1,094,352.70. The trade was a 43.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 314,560 shares of company stock worth $12,362,568 over the last quarter. Company insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Private Trust Co. NA purchased a new position in uniQure in the 3rd quarter valued at $28,000. Jones Financial Companies Lllp boosted its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. Main Management ETF Advisors LLC increased its stake in shares of uniQure by 1.6% during the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after acquiring an additional 912 shares during the period. Profund Advisors LLC raised its holdings in uniQure by 24.6% during the third quarter. Profund Advisors LLC now owns 17,084 shares of the biotechnology company’s stock worth $997,000 after purchasing an additional 3,368 shares in the last quarter. Finally, Westfield Capital Management Co. LP acquired a new stake in uniQure in the third quarter valued at about $223,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.